Advancement in HCC imaging: Diagnosis, staging and treatment efficacy assessments. Hepatocellular carcinoma: Imaging in assessing treatment efficacy

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 17, Issue 4, 2010, Pages 374-379

  Vilgrain, Valérie ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BEAUJON HOSPITAL   (France)

^c CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

Author keywords

Liver neoplasms, HCC; Liver neoplasms, imaging; Liver neoplasms, treatment

Indexed keywords

CISPLATIN; DOXORUBICIN; SORAFENIB; SUNITINIB;

ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG EFFICACY; HEPATOGRAPHY; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOFREQUENCY ABLATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR ABLATION; TUMOR GROWTH; CANCER STAGING; CATHETER ABLATION; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; LIVER TUMOR; METHODOLOGY; REVIEW;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 79952110856     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1007/s00534-009-0230-3     Document Type: Article

References (34)

1. Bruix J, Sherman M. Practice guidelines committee, American Association for the study of liver diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208-36.
2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693-9. (Pubitemid 26079803)
3. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25(2):181-200. (Pubitemid 40781071)
4. Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol. 2006;101(3):513-23. (Pubitemid 43340927)
5. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: longterm results of treatment and prognostic factors. Ann Surg. 1999;229(2):216-22. (Pubitemid 30191795)
6. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200-7. (Pubitemid 36169630)
7. Willat JM, Hussain HK, Adusumilli S, Marrero JA. MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies hepatitis. Radiology. 2008;247:311-30.
8. Hecht EM, Holland AE, Israel GM, et al. Hepatocellular carcinoma in the cirrhotic liver: gadolinium enhanced 3D T1-weighted MR imaging as a stand-alone sequence for diagnosis. Radiology. 2006;239:438-47.
9. Llovet JM, Di Bisceglie AM, Bruix J. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698-711.
10. Dharancy S, Boitard J, Decaens T, Sergent G, Boleslawski E, Duvoux C, et al. Comparison of two techniques of transarterial chemoembolization before liver transplantation for hepatocellular carcinoma: a case-control study. Liver Transpl. 2007;13(5):665-71. (Pubitemid 46796537)
11. Vogl TJ, Trapp M, Schroeder H, Mack M, Schuster A, Schmitt J, et al. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center. Radiology. 2000;214(2):349-57. (Pubitemid 30077688)
12. Takayasu K, Muramatsu Y, Maeda T, Iwata R, Furukawa H, Muramatsu Y, et al. Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates. AJR Am J Roentgenol. 2001;176(3):681-8. (Pubitemid 32181966)
13. Katyal S, Oliver JH, Peterson MS, Chang PJ, Baron RL, Carr BI. Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: a retrospective analysis. AJR Am J Roentgenol. 2000;175(6):1665-72.
14. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol. 2001;35(3):421-30. (Pubitemid 32844200)
15. Ernst O, Sergent G, Mizrahi D, Delemazure O, Paris JC, L'Herminé C. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. AJR Am J Roentgenol. 1999;172(1):59-64. (Pubitemid 29028431)
16. Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol. 2007;5(9):1100-8.
17. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321-8. (Pubitemid 43327762)
18. Lu MD, Kuang M, Liang LJ, Xie XY, Peng BG, Liu GJ, et al. Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial. Zhonghua Yi Xue Za Zhi. 2006;86:801-5.
19. Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47:82-9.
20. Choi D, Lim HK, Rhim H, Kim YS, Lee WJ, Paik SW, et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a firstline treatment: long-term results and prognostic factors in a large single institution series. Eur Radiol. 2007;17:684-92.
21. Lupo L, Panzera P, Giannelli G, Memeo M, Gentile A, Memeo V. Single hepatocellular carcinoma ranging from 3 to 5 cm: radiofrequency ablation or resection? HPB. 2007;9:429-34.
22. Nakazawa T, Kokubu S, Ono K, et al. radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin AJR 2007;188:480-88.
23. Okusaka T, Okada S, Ueno H, et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer. 2002;95:1931-7. (Pubitemid 35222173)
24. Catalano O, Lobianco R, Esposito M, Siani A. Hepatocellular carcinoma recurrence after percutaneous ablation therapy: helical CT patterns. Abdom Imaging. 2001;26:375-83. (Pubitemid 32565867)
25. Goldberg SN, Grassi CJ, Cardella JF, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology. 2005;235:728-39. (Pubitemid 40695866)
26. Dromain C, de Baere T, Elias D, et al. Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. Radiology. 2002;223(1):255-62. (Pubitemid 34258217)
27. Brillet PY, Paradis V, Brancatelli G, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma before liver transplantation: a prospective study with histopathologic comparison. AJR Am J Roentgenol. 2006;186:S296-305.
28. Lu DS, Yu NC, Raman SS, et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology. 2005; 234(3):954-60. (Pubitemid 40250843)
29. Martin AP, Goldstein RM, Dempster J, et al. Radiofrequency thermal ablation of hepatocellular carcinoma before liver transplantation - a clinical and histological examination. Clin Transplant. 2006;20(6):695-705. (Pubitemid 44712269)
30. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;24, 359(4):378-90.
31. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34.
32. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293-300. (Pubitemid 46630787)
33. Horger M, Lauer UM, Schraml C, et al. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer. 2009;9(1):208.
34. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753-9. (Pubitemid 46797957)